title: The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective-author response to letter to the editor.
authors: Medical Decision Modeling, Inc., Indianapolis, IN, USA.
authors: Ronald C
authors: RC
authors: Wielage
authors: Megha
authors: M
authors: Bansal
authors: J
authors: J
authors: Scott Andrews
authors: Madelaine M
authors: MM
authors: Wohlreich
authors: Robert W
authors: RW
authors: Klein
authors: Michael
authors: M
authors: Happich
mesh_terms: D000701:Analgesics, Opioid / Q000191:economics*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics*; D000927:Anticonvulsants / Q000191:economics*; D006801:Humans; D007348:Insurance, Health / Q000191:economics*; D017116:Low Back Pain / Q000191:economics*; D017367:Selective Serotonin Reuptake Inhibitors / Q000191:economics*; D013876:Thiophenes / Q000191:economics*
chemical_list: D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000927:Anticonvulsants; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes